Kiora Pharmaceuticals (KPRX) Net Cash Flow (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Net Cash Flow came in at $2.2 million in Q1 2026, up 7226.1% YoY from $30559.3 in Q1 2025, and down 29.35% on a QoQ basis from $3.2 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Net Cash Flow (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Net Cash Flow data on file, last reported at $2.2 million in Q1 2026.
- Quarterly Net Cash Flow rose 7226.1% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.0 million (up 125.45% YoY) and the FY2025 annual result came in at $4.7 million, up 239.23% from the prior year.
- Net Cash Flow declined to $2.2 million in Q1 2026, from $3.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $28.9 million in Q1 2024 to a low of -$24.7 million in Q2 2024.
- A 5-year average of $174874.6 and a median of -$1.0 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow slumped 642.51% — and 2026, when it soared 7226.1%.
- Tracing KPRX's Net Cash Flow over 5 years: stood at $1.1 million in 2022, then slumped by 375.33% to -$3.1 million in 2023, then surged by 42.31% to -$1.8 million in 2024, then soared by 279.07% to $3.2 million in 2025, then slipped by 29.35% to $2.2 million in 2026.
- The last three Net Cash Flow figures came in at $2.2 million (Q1 2026), $3.2 million (Q4 2025), and $4.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | -3.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -3.86 Mn |
| Jun 30, 2026 | -3.86 Mn |
| Mar 31, 2026 | 2.24 Mn |
| Mar 31, 2026 | 2.24 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Dec 31, 2025 | 3.17 Mn |
| Sep 30, 2025 | 4.47 Mn |
| Sep 30, 2025 | 4.47 Mn |
| Jun 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -2.87 Mn |
| Mar 31, 2025 | -31,417.00 |
| Mar 31, 2025 | -31,417.00 |
| Dec 31, 2024 | -1.77 Mn |
| Dec 31, 2024 | -1.77 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Sep 30, 2024 | -1.00 Mn |
| Jun 30, 2024 | -24.71 Mn |
| Jun 30, 2024 | -24.71 Mn |
| Mar 31, 2024 | 28.87 Mn |
| Mar 31, 2024 | 28.87 Mn |